MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Why Did GSK Pay $10.6 Billion for Nuvalent

4 days ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Why Did Gilead Pay $7.8 Billion for Arcellx

3 months ago

Why Did Google Pay a Record-Breaking $32 Billion for Wiz

3 months ago

Why Did Alphabet Pay a Record $32 Billion for Wiz

3 months ago

What's Behind Whoop's Soaring $10 Billion Valuation

2 months ago

After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal

GSK is rebuilding its oncology business with a $10.6 billion deal, a decade after shedding it.

GSK

Stock News•4 days ago

NUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders

Nuvalent (NUVL) is under investigation by Halper Sadeh LLC over its $124/share cash sale to GSK, focusing on whether the board obtained a fair price for shareholders.

NUVL

Stock News•4 days ago

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

GSK will acquire Nuvalent for $10.6 billion, gaining three lung cancer drug candidates, including two under FDA review for approval this year.

GSK

Stock News•1 months ago

Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal

Nuvalent maintains a $1.37B cash position following a $500M raise, extending its operational runway through 2029. The company is advancing two precision oncology assets, with a PDUFA date for zidesamt...

NUVL